<DOC>
	<DOCNO>NCT00362297</DOCNO>
	<brief_summary>The purpose research study evaluate effectiveness high-dose acyclovir compare valacyclovir reduction asymptomatic genital shed person genital herpes . The study enroll men woman 18 year old , test positive HSV-2 ( blood test ) first outbreak HSV-2 within past 6 month least 4 genital herpes outbreak past year . Participants must HIV negative willing stop take suppressive therapy HSV one week wash period . ( Females : You must pregnant breast-feeding ) . Both men woman ask use effective form birth control . Involvement study last 15-weeks ask visit clinic every 2-weeks . At visit , give medication take daily ( either valacyclovir acyclovir ; receive medication point study ) . There total 9 study visit visit last approximately 30 minute . We ask complete daily symptom diary collect daily home swab 4-times day , everyday study . Each daily home swab take less 3 minute perform .</brief_summary>
	<brief_title>Randomized Trial Evaluate Suppressive Effect High-Dose Acyclovir Versus Once-Daily Valacyclovir Persons With HSV-2</brief_title>
	<detailed_description>Screening Assessment Patients assess eligibility enter study screen visit . After sign informed consent undergo medical history follow information record Case Report Form ( CRF ) : - Demographic Data : Date birth , sex , marital status , education race - Previous antiviral medication take - History sexually transmit infection sexual history . Start Study Visit ( Day 0 ) Day 14 , 28 , 42 , 56 , 70 , 84 , 98 105 Follow-Up Visits . Eligible patient return clinic give study drug patient diary card record concomitant medication , sign symptom , adverse experience . The investigator instruct patient daily home viral sample collection , take study drug , complete diary card . The patient instruct return clinic 2 week , +/- 2 day . Medication compliance assess visit use pill count . Crossover Study Visit Prior To Washout Period ( Day 49-55 ) Participants give study drug placebo 7-day washout period . Daily Home Viral Sample Collection Participants collect swabs genital mucosa four time per day store sample PCR medium preprinted label . Women swab cervicovaginal , vulvar perianal area , men swab penile perianal . Every two week , return sample Virology Research Clinic present additional study drug assessment . Final Study Visit ( Day 105 ) At final study visit Day 105 premature discontinuation , investigator perform activity regular study visit , exception dispensation study drug .</detailed_description>
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<criteria>1 . 18 year old ; 2 . HSV2 seropositive Western Blot ; 3. receive drug know antiHSV2 activity study duration ; 4. history primary genital herpes infection within past 6 month OR history 4 HSV recurrence per year past year OR 4 recurrence per year prior initiation suppressive antiviral therapy ; 5. able comply study protocol ; 6. woman child bear potential sexually active men must use medically accept method contraception judge investigator ; 7. woman childbearing potential must negative pregnancy test ( urine ) screen visit ; 8. general good health , without serious medical condition specifically normal renal hepatic function , determine patient 's medical history ; 9. planning remain resident area study center duration study participation ; 10 . HIV seronegative . 1. hypersensitivity acyclovir valacyclovir ; 2. pregnant woman ; 3 . HIV positive immunosuppressed state , include chronic steroid use . Intermittent nasal topical steroid acceptable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>